Federal Supreme Court upholds its stricter Pfizer case law (V2)

In its last week's published decisions, the Federal Supreme Court upheld its stricter case law on the permissibility of price recommendations and vertical price agreements thereby confirming its Pfizer practice.

Marcel Meinhardt and his team represent Pfizer in this proceeding before the Competition authorities.

Read more:
Federal Supreme Court's decision, 7 October 2021 (2C_145/2018) – Eli Lilly (Suisse) SA
Federal Supreme Court's decision, 7 October 2021 (2C_147/2018) – Bayer (Schweiz) AG
Kluwer Competition Law Blog, 6 July 2021
Lenz & Staehelin Update Newsflash, 22 April 2021

Published: 1 November 2021